IGC Pharma
32 hedge funds and large institutions have $7.9M invested in IGC Pharma in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
20% more call options, than puts
Call options by funds: $823K | Put options by funds: $687K
10% more funds holding
Funds holding: 29 → 32 (+3)
0.5% more ownership
Funds ownership: 9.95% → 10.45% (+0.5%)
0% more capital invested
Capital invested by funds: $7.9M → $7.9M (+$4K)
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$654K |
| 2 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
+$484K |
| 3 |
Renaissance Technologies
New York
|
+$224K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$156K |
| 5 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$91.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$280K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$193K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$113K |
| 4 |
PCM
Penserra Capital Management
Orinda,
California
|
-$98K |
| 5 |
State Street
Boston,
Massachusetts
|
-$76.1K |
IGC Hedge Fund Activity: Q3 2021 in Review
32 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q3 2021, worth a combined $7.9M — up 0.05% from $7.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new IGC positions and 3 closed out — a net gain of 3 holders — while 7 added to existing stakes and 12 trimmed.
The largest buyer was Mirae Asset Global Investments, opening a new position worth an estimated $654K. The largest seller was Virtu Financial, cutting an estimated $280K.
- 32 institutional investors held IGC Pharma (IGC) as of Q3 2021, up from 29 in Q2 2021.
- Funds reported $7.9M of IGC Pharma stock for Q3 2021, up 0.05% quarter-over-quarter.
- 6 funds opened new IGC Pharma positions in Q3 2021 and 3 closed out, a net change of +3 holders.
- The largest IGC Pharma buyer in Q3 2021 was Mirae Asset Global Investments, an estimated $654K added.
- The largest IGC Pharma seller in Q3 2021 was Virtu Financial, an estimated $280K sold.
Based on aggregated 13F filings for Q3 2021.